GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Readout] REDEFINE 1 and what CagriSema actually adds over sema alone — 35 comments in the full submission. View in context.
915
c/trialwatch·submitted 14 days ago by u/week_one_wanda

[Readout] REDEFINE 1 and what CagriSema actually adds over sema alone

Readoutbranch of 8 comments

Week 43 update. 34kg down from the start, reflux basically gone since about week 95. Things that worked: consistency, protein at breakfast, walking more than I want to. Things that did not: everything I bought on the internet to help with reflux. The part that surprised me is how much of this is admin. Ordering,…

Read the full submission and all 35 comments →

This branch

8 comments, started 14 days ago
u/yannick_salinas112 points·14 days ago

Strongly agree. Phase 2 is investigational, not conclusive.

replysharereportpermalink
u/kaia_cabrera36 points·14 days ago·edited

What was the dropout rate?

replysharereportpermalink
u/camila_vasquez11 points·14 days ago

absolute risk reduction, not relative risk reduction, that is how you decide

replysharereportpermalink
u/week_one_wandaOP63 points·14 days ago

Phase 2 TRIUMPH looked amazing. Phase 3 trials are harder. Do not anchor on phase 2 readouts.

replysharereportpermalink
u/nikhil_lindqvist91 points·13 days ago

Small correction: the trial was 12 weeks, not 38. Does not change your point but people will quote it.

replysharereportpermalink
u/renal_outcomes_rnephro-curious50 points·13 days ago

Disagree. What you are describing is consistent with SURPASS, not with what you concluded.

replysharereportpermalink
u/week_one_wandaOP19 points·13 days ago

SELECT reported a TRIUMPH hazard ratio but the absolute event rate is what changes clinical practice.

replysharereportpermalink
u/slow_logbook_notes3018 points·13 days ago

Phase 2 TRIUMPH looked amazing.

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →